Targeting Melanoma with a Novel Tumor-Specific Immune Checkpoint Blocker
A tumor-targeted immune checkpoint blocker.
Background
Immune checkpoint inhibitors (ICIs), such as anti-PD-L1 antibodies, have revolutionized cancer immunotherapy by unleashing the body's immune response against tumors. However, their systemic administration can lead to widespread immune activation, resulting in significant off-target toxicities and immune-related adverse events in patients. This study addresses the critical need to develop strategies that localize immune checkpoint blockade specifically to the tumor microenvironment, thereby minimizing systemic side effects while maximizing therapeutic efficacy.
Study Design
Population
The study aims to develop strategies for localizing immune checkpoint blockade to the tumor microenvironment in cancer patients.
Intervention
The intervention involves novel strategies for localizing immune checkpoint blockade, specifically anti-PD-L1 antibodies, to the tumor microenvironment.
Outcome
The primary outcome is to minimize systemic side effects while maximizing therapeutic efficacy of immune checkpoint inhibitors.